PharmaCyte Biotech authorizes new $10M share repurchase program

PharmaCyte Biotech, Inc.

Board authorized repurchase of up to $10M of common stock, effective immediately for two years.
Prior program (June 2022) repurchased ~3.41M shares for ~$9.3M as of filing date.
Program will be funded from available cash; CEO cites strong balance sheet and shareholder commitment.
Company continues evaluating internal programs and exploring strategic opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.